GlassScriptPhysician profile
Evan M Collins
NPI 1801828439
$896.97
in general payments reported to CMS, 2019-2025
19 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $88.16 · 2021: $140 · 2022: $79.76 · 2023: $53.46 · 2024: $177 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $175.66 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $117.18 | 2022-2025 | |
| Pfizer INC. | $99.99 | 2019-2020 | |
| Hologic Sales and Service, LLC | $80.20 | 2021-2025 | Aptima, Acessa Provu System |
| Exact Sciences Corporation | $64.16 | 2024 | Cologuard Collection Kit |
| Cook Medical LLC | $43.03 | 2025 | Zilver Ptx, Cook |
| Mylan Pharmaceuticals INC. | $42.30 | 2019 | |
| Sumitomo Pharma America, INC. | $42.03 | 2024-2025 | Myfembree |
| Amgen INC. | $38.93 | 2019-2020 | |
| Coopersurgical, INC. | $37.04 | 2019-2024 | Paragard T 380a |
| Millicent US INC | $34.71 | 2020-2024 | Femring, Intrarosa |
| Organon LLC | $30.20 | 2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $24.50 | 2023 | |
| Evofem Biosciences, INC. | $18.07 | 2021 | |
| Astellas Pharma US INC | $12.81 | 2023 | Veozah |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $12.21 | 2020 | |
| Therapeuticsmd, INC. | $12.10 | 2019 | |
| Allergan, INC. | $11.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.